Skip to Main Content

Jewish Hospital Celebrates 100th TAVR Procedure - Archived


WHAT:   Patients and Physicians Celebrate 100th Transcatheter Aortic Valve Replacement (TAVR) procedure at
             Jewish Hospital, part of KentuckyOne Health.  This procedure is a lifesaving treatment option for
             patients needing valve replacement who are not well enough to undergo traditional open-heart surgery.


WHEN:    Wednesday, March 12, 2014
              at 2:30 p.m.


WHERE:   Jewish Hospital Rudd Heart and Lung Center
              201 Abraham Flexner Way
              Conference Center (CC)


  • Photos, interviews and b-roll of patients who have received lifesaving valve replacement through this innovative new procedure
  • Remarks from Mark Slaughter, M.D., executive director of cardiovascular services for the KentuckyOne Health Louisville market, Chair of the Department of Cardiovascular and Thoracic Surgery at the University of Louisville
  • Interviews with Matthew Williams, M.D., Director of Clinical Cardiac Operations, Kendra Grubb, M.D., Director of Minimally Invasive Cardiac Surgery, and other physicians who perform the TAVR procedure


MORE:      TAVR is a catheter-based aortic valve replacement procedure that offers an alternative to traditional, open
              heart surgery in eligible patients. The TAVR program has been successful in treating patients who were not
              candidates for traditional open-heart surgery due to advanced age, or other risk factors.




Jewish Hospital, a part of KentuckyOne Health, is an internationally renowned high-tech tertiary referral center developing leading-edge advancements in hand and microsurgery, heart and lung care, cancer care, home care, rehab medicine, sports medicine, orthopaedics, neuroscience, occupational health, organ transplantation and outpatient and primary care.  Site of the world’s first successful hand transplant, the world’s first and second successful AbioCor® Implantable Replacement Heart procedures, and world’s first trial of cardiac stem cells in chronic heart failure, the hospital is in the select group that performs heart, lung, liver, kidney and pancreas transplantation.



Publish date: 

Wednesday, March 12, 2014